289
Participants
Start Date
April 1, 2021
Primary Completion Date
December 31, 2023
Study Completion Date
December 31, 2026
Lenalidomide
25mg po on day 1-10
Cyclophosphamide
750mg/m² iv on day1
Doxorubicin
50mg/m² iv on day 1
Vincristine
1.4mg/m² iv on day 1
Prednisone
100mg po on day1-5
RECRUITING
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou
Ruijin Hospital
OTHER
Xinqiao Hospital of Chongqing
OTHER
Union hospital of Fujian Medical University
OTHER
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Southern Medical University, China
OTHER
Shandong Provincial Hospital
OTHER_GOV
Huashan Hospital
OTHER
First Hospital of China Medical University
OTHER
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
OTHER
Henan Provincial People's Hospital
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Changhai Hospital
OTHER
The Affiliated Hospital of Xuzhou Medical University
OTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
RenJi Hospital
OTHER
Zhongda Hospital
OTHER
The First Affiliated Hospital of Anhui Medical University
OTHER
Hunan Cancer Hospital
OTHER
First Affiliated Hospital of Harbin Medical University
OTHER
Xiangya Hospital of Central South University
OTHER
The First Affiliated Hospital of Dalian Medical University
OTHER
Jilin Provincial Tumor Hospital
OTHER
Shanxi Province Cancer Hospital
OTHER
Zhongshan Hospital Xiamen University
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER